Skip to main content

Table 1 Baseline characteristics of study participants

From: A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

Variable 1:1 (n = 19) Group-Supervised (n = 16) Home-Based (N = 18) P-value
Age (years), mean (SD) 69.2 (7.3) 71.5 (7.2) 69.6 (8.1) 0.59
Education, post-secondary, n (%) 14 (73.7) 15 (93.8) 11 (61.1) 0.085
Race, White, n (%) 12 (63.2) 14 (87.5) 12 (66.7) 0.59
Marital Status, married (%) 13 (68.4) 14 (87.5) 10 (55.6) 0.63
Working Status, retired (%) 11 (57.9) 9 (56.3) 13 (72.2) 0.44
Smoking Status, never smoked (%) 6 (31.6) 8 (50.0) 7 (38.9) 0.52
ECOG Performance Status, 0–1(%) Missing 17 (100.0) 15 (100.0) 14 (92.7) 0.64
2 1 3
Karnofsky Score, mean % (SD) 81 (11.1) 87 (9.9) 79 (9.2) 0.082
PSA at diagnosis, ng/mL, median (IQR) 9 (7–20) 10 (8–17) 15 (6–35) 0.34
Charlson Comorbidity score, n (%) 0 11 (57.9) 13 (81.3) 15 (83.3) 0.23
1 6 (31.6) 3 (18.7) 0
≥2 1 (5.3) 0 1 (5.5)
Missing 1 (5.3) 0 2 (11.0)
Clinical Stage, n (%) T1-T2 9 (56.3) 9 (60.0) 9 (52.9) 0.99
T3+ 6 (37.5) 5 (33.3) 7 (41.2)
Missing 4 2 2
Gleason score, n (%) 6 3 (21.4) 1 (6.7) 1 (5.9) 0.18
7 4 (28.6) 4 (26.7) 10 (58.8)
8–10 7 (50.0) 10 (66.7) 6 (35.3)
Missing 5 1 1
Duration of ADT, n (%) < 3 mo. 5 (26.3) 2 (16.7) 6 (33.3) 0.59
≥3 mo. 14 (73.7) 10 (83.3) 12 (66.7)
Missing 0 4 0
Indication for ADT, n (%) Adjuvant 10 (52.6) 7 (43.8) 8 (44.4) 0.62
Biochemical relapse 3 (15.8) 5 (31.3) 7 (38.9)
Metastases 2 (10.5) 2 (12.5) 0
Unknown 4 (21.1) 2 (12.5) 3 (16.7)
FACT-G (total), mean (SD) 84.2 (17.5) 85.9 (10.4) 85.4 (12.3) 0.93
FACT-P (total), mean (SD) 118.6 (23.9) 119.9 (14.5) 120.4 (17.8) 0.96
FACT-Fatigue, mean (SD) 41.0 (10.4) 39.5 (8.1) 39.1 (11.0) 0.84
VO2peak (L/min), mean (SD) 1.7 (0.4) 1.9 (0.5) 1.8 (0.5) 0.81
Grip strength, mean (SD) 28.6 (5.7) 32.6 (8.3) 33.9 (10.3) 0.13
Timed chair stands, mean (SD) 24.5 (7.7) 24.8 (10.0) 23.7 (6.3) 0.90